TiLoop Bra
DeviceTitaniferously coated polypropylene mesh
NCT Number: NCT01885572
This multicentre, non-randomised, observational clinical device investigation will be performed to obtain postmarketing information on the TiLOOP® Bra and in particular on the improvement of the patients' quality of life as well as on the rate of complications of the device under investigation.
The objective of this clinical investigation is to establish the feasibility, efficacy and safety of the TiLOOP® Bra.
Looking for future studies?
Notify Me18 year–70 year
Female
Interventional
Not applicable
Charite Campus Mitte and Benjamin Franklin, Berlin, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The TiLOOP®Bra is designed to assist oncologically indexed skin sparing mastectomy or subcutaneous mastectomy with preservation of the nipple-areola-complex during primary breast reconstruction, secondary breast reconstruction or corrective breast surgery. Patients shall be included if they meet all of the following criteria:
Clinical Criteria (reason):
Study-related inclusion criteria - Legal reasons:
Exclusion criteria
Patients must be excluded if any of the following conditions exist or cannot be excluded:
Device-related exclusion criteria (contraindications):
Pathological or physical condition precluding such as:
Study-related exclusion criteria - Medical reasons:
Study-related exclusion criteria - Legal reasons:
It is thought that the study-related exclusion criteria will not significantly influence the sample of the population under investigation.
Titaniferously coated polypropylene mesh
Time frame: 12 months after breast reconstruction
Measurement of the Patient Reported Outcome (PRO).
Time frame: 6 and 24 months after breast reconstruction
Measurement of the Patient Reported Outcome
Time frame: after 6, 12 and 24 months
Complication rate of the first 60 patients in the 6 month follow-up and of all patients after 6, 12 and 24 months.
Time frame: 6, 12 and 24 months after breast reconstruction
Cosmetic success confirming the reinforcement will be assessed by the patient and an independent professional at a photo. The questions posed are part of the validated Breast Q questionnaire.
Time frame: 48 months after breast reconstruction
Measurement of the Patient Reported Outcome and complication rate of all patients
Pfm Medical Mepro Gmbh
Industry
National, Multicenter Post-market Surveillance Study "Patient Reported Outcome" in Breast Reconstruction Following Mastectomy With Titaniferously Coated Polypropylene Mesh (TiLOOP Bra)
Acronym: PRO-BRA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03868514
Breast Cancer, Breast Diseases
Vienna, Austria
View Trial DetailsNCT07641985
Breast Cancer, Breast Cancer Radiation
Maastricht, Limburg, Netherlands
View Trial DetailsNCT07365267
3D-Printed Biodegradable Biological Mesh, Breast Cancer
Xi'an, Shaanxi, China
View Trial DetailsNCT07516483
Breast Reconstruction After Mastectomy
Winston-Salem, North Carolina, United States
View Trial Details